semaglutide bcs class Transporter effects on drug disposition by BCS class Oral semaglutide (Rybelsus) is the

The specific marketing approval dates for these GLP-1 RAs are shown in Supplementary Table S1

Pantoprazole is a proton pump inhibitor (PPI) that works by reducing the amount of acid produced in the stomach, making it an effective treatment for various acid-related gastrointestinal conditions such as gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and erosive esophagitis

In other words, claims on the label may not accurately reflect whats in the product

Semaglutide exposure was associated with a hazard ratio of 2.22 approximately twice the hazard compared with nonGLP-1 RA use across the full study period